MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
7.28
-0.21 (-2.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.49
Open7.43
Bid6.05 x 100
Ask0.00 x 0
Day's Range7.22 - 7.46
52 Week Range4.40 - 7.88
Volume18,440
Avg. Volume134,050
Market Cap262.813M
Beta0.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What You Must Know About MediciNova Inc’s (NASDAQ:MNOV) Major Investors
    Simply Wall St.3 days ago

    What You Must Know About MediciNova Inc’s (NASDAQ:MNOV) Major Investors

    In this analysis, my focus will be on developing a perspective on MediciNova Inc’s (NASDAQ:MNOV) latest ownership structure, a less discussed, but important factor. Ownership structure has been found toRead More...

  • Does MediciNova Inc’s (NASDAQ:MNOV) CEO Pay Compared Well With Peers?
    Simply Wall St.10 days ago

    Does MediciNova Inc’s (NASDAQ:MNOV) CEO Pay Compared Well With Peers?

    Yuichi Iwaki took the reins as CEO of MediciNova Inc’s (NASDAQ:MNOV) and grew market cap to $252.71M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • MediciNova Inc (NASDAQ:MNOV): What’s The Analyst Consensus Outlook?
    Simply Wall St.17 days ago

    MediciNova Inc (NASDAQ:MNOV): What’s The Analyst Consensus Outlook?

    The latest earnings update MediciNova Inc’s (NASDAQ:MNOV) released in September 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below isRead More...

  • Does MediciNova Inc’s (NASDAQ:MNOV) Past Performance Indicate A Stronger Future?
    Simply Wall St.27 days ago

    Does MediciNova Inc’s (NASDAQ:MNOV) Past Performance Indicate A Stronger Future?

    After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compareRead More...

  • Zacks Small Cap Researchlast month

    MNOV: Positive Topline Results for MN-166 in P2 ALS Study

    The primary endpoint of the study (safety and tolerability) was achieved and there were efficacy trends in key functional secondary endpoints that favored MN-166. This was a single center, double blind, placebo controlled six-month study with patients randomized 2:1 to receive riluzole (100 mg/day) plus either MN-166 (60 mg/day) or placebo. The six-month double blind portion was followed by a six-month open label extension phase during which all patients received MN-166.

  • MarketWatchlast month

    MediciNova stock up more than 50% on positive trial results

    Biotech company MediciNova Inc. said late Thursday that it had received positive top-line results from the company's clinical trial of MN-166 in amyotrophic lateral sclerosis. Shares went on a rampage ...

  • Is MediciNova Inc (MNOV) Cheap And High Growth?
    Simply Wall St.2 months ago

    Is MediciNova Inc (MNOV) Cheap And High Growth?

    MediciNova Inc (NASDAQ:MNOV), a USD$251.26M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoingRead More...

  • Is MediciNova Inc (MNOV) Undervalued?
    Simply Wall St.2 months ago

    Is MediciNova Inc (MNOV) Undervalued?

    MediciNova Inc (NASDAQ:MNOV), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. As aRead More...

  • Zacks Small Cap Research6 months ago

    MNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study

    On June 5, 2017, MediciNova (MNOV) announced that Professor Kerrie McDonald presented results from a preclinical study of MN-166 (ibudilast) in the treatment of glioblastoma (GBM) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Proteomic profiling of samples from 30 GBM patients revealed macrophage inhibitory factor (MIF) as a protein that was expressed in “poor responders” (e.g., those that lived

  • Zacks Small Cap Research11 months ago

    MNOV: MN-166 Making Progress in Numerous Indications…

    There have been a number of recent announcements regarding MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. - On February 7, 2017, MediciNova, Inc. (MNOV) announced that an abstract regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, which is taking place from Apr. 22-28, 2017 in Boston, Massachusetts. - On December 20, 2016, MediciNova announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 for the treatment of ALS.